Latest Insider Transactions at Gemini Therapeutics, Inc. (GMTX)
This section provides a real-time view of insider transactions for Gemini Therapeutics, Inc. (GMTX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Gemini Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Gemini Therapeutics, Inc. 's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 17
2024
|
Kevin Bitterman |
BUY
Open market or private purchase
|
Indirect |
222,223
+34.57%
|
$8,000,028
$36.0 P/Share
|
|
Jun 17
2024
|
Mona Ashiya Director |
BUY
Open market or private purchase
|
Indirect |
83,334
+4.46%
|
$3,000,024
$36.0 P/Share
|
|
Jun 17
2024
|
Orbimed Advisors LLC Director |
BUY
Open market or private purchase
|
Indirect |
83,334
+4.46%
|
$3,000,024
$36.0 P/Share
|
|
Jun 17
2024
|
Ai Dmi LLC |
BUY
Grant, award, or other acquisition
|
Direct |
416,667
+10.48%
|
$15,000,012
$36.0 P/Share
|
|
Jun 03
2024
|
William Richard White |
SELL
Open market or private sale
|
Direct |
1,957
-66.78%
|
$68,495
$35.99 P/Share
|
|
Jun 03
2024
|
William Richard White |
BUY
Exercise of conversion of derivative security
|
Direct |
1,957
+29.66%
|
$11,742
$6.26 P/Share
|
|
May 01
2024
|
William Richard White |
SELL
Open market or private sale
|
Direct |
201
-90.3%
|
$5,628
$28.82 P/Share
|
|
May 01
2024
|
William Richard White |
BUY
Exercise of conversion of derivative security
|
Direct |
201
+50.0%
|
$1,809
$9.86 P/Share
|
|
Apr 11
2024
|
William Richard White |
SELL
Open market or private sale
|
Direct |
2,560
-98.48%
|
$79,360
$31.99 P/Share
|
|
Apr 11
2024
|
William Richard White |
BUY
Exercise of conversion of derivative security
|
Direct |
2,560
+36.95%
|
$15,360
$6.26 P/Share
|
|
Apr 10
2024
|
William Jacob Savage Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
21,870
+33.5%
|
$43,740
$2.65 P/Share
|
|
Mar 05
2024
|
Kevin Bitterman |
SELL
Open market or private sale
|
Indirect |
26,157
-3.72%
|
$1,909,461
$73.5 P/Share
|
|
Feb 26
2024
|
Pamela Stephenson Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
36,666
+50.0%
|
-
|
|
Feb 07
2024
|
Jean M. Franchi Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
36,666
+50.0%
|
-
|
|
Jan 23
2024
|
Atlas Venture Fund X, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
102,500
-9.83%
|
$6,867,500
$67.65 P/Share
|
|
Jan 23
2024
|
Atlas Venture Fund X, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
47,500
-3.28%
|
$3,182,500
$67.65 P/Share
|
|
Jan 23
2024
|
Kevin Bitterman |
SELL
Open market or private sale
|
Indirect |
102,500
-9.83%
|
$6,867,500
$67.65 P/Share
|
|
Jan 10
2024
|
Joanne Bryce Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
18,165
+43.43%
|
-
|
|
Jan 10
2024
|
John D Quisel Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
66,365
+49.0%
|
-
|
|
Jan 10
2024
|
William Jacob Savage Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
18,535
+46.26%
|
-
|
|
Jan 10
2024
|
Jonathan Yen Wen Yu Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
18,165
+50.0%
|
-
|
|
Jan 10
2024
|
Rahul Khara General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
14,035
+50.0%
|
-
|
|
Jan 10
2024
|
Atlas Venture Fund X, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
20,000
-2.48%
|
$1,280,000
$64.0 P/Share
|
|
Jan 10
2024
|
Atlas Venture Fund X, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
30,000
-2.03%
|
$1,920,000
$64.0 P/Share
|
|
Jan 10
2024
|
Kevin Bitterman |
SELL
Open market or private sale
|
Indirect |
20,000
-2.48%
|
$1,280,000
$64.0 P/Share
|
|
Dec 29
2023
|
John D Quisel Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,700
+50.0%
|
$2,700
$1.01 P/Share
|
|
Dec 27
2023
|
Joanne Bryce Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,000
+35.29%
|
$27,000
$9.86 P/Share
|
|
Dec 18
2023
|
Orbimed Advisors LLC Director |
SELL
Open market or private sale
|
Direct |
1,724
-100.0%
|
$101,716
$59.24 P/Share
|
|
Dec 18
2023
|
Orbimed Advisors LLC Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,724
+50.0%
|
$65,512
$38.0 P/Share
|
|
Dec 18
2023
|
Mona Ashiya Director |
SELL
Open market or private sale
|
Direct |
1,724
-100.0%
|
$101,716
$59.24 P/Share
|
|
Dec 18
2023
|
Mona Ashiya Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,724
+50.0%
|
$65,512
$38.0 P/Share
|
|
Dec 14
2023
|
Orbimed Advisors LLC Director |
SELL
Open market or private sale
|
Indirect |
433,400
-12.18%
|
$24,703,800
$57.14 P/Share
|
|
Dec 14
2023
|
Mona Ashiya Director |
SELL
Open market or private sale
|
Indirect |
433,400
-12.18%
|
$24,703,800
$57.14 P/Share
|
|
Dec 14
2023
|
Kevin Bitterman |
SELL
Open market or private sale
|
Indirect |
20,549
-1.24%
|
$1,212,391
$59.01 P/Share
|
|
Dec 14
2023
|
Atlas Venture Fund X, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
20,549
-1.24%
|
$1,212,391
$59.01 P/Share
|
|
Dec 14
2023
|
Atlas Venture Fund X, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
30,825
-1.02%
|
$1,818,675
$59.01 P/Share
|
|
Dec 13
2023
|
Kevin Bitterman |
SELL
Open market or private sale
|
Indirect |
3,548
-0.21%
|
$212,880
$60.25 P/Share
|
|
Dec 13
2023
|
Atlas Venture Fund X, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
3,548
-0.21%
|
$212,880
$60.25 P/Share
|
|
Dec 13
2023
|
Atlas Venture Fund X, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
5,323
-0.18%
|
$319,380
$60.25 P/Share
|
|
Dec 13
2023
|
Orbimed Advisors LLC Director |
SELL
Open market or private sale
|
Indirect |
106,700
-4.76%
|
$6,188,600
$58.56 P/Share
|
|
Dec 13
2023
|
Mona Ashiya Director |
SELL
Open market or private sale
|
Indirect |
106,700
-4.76%
|
$6,188,600
$58.56 P/Share
|
|
Dec 12
2023
|
Kevin Bitterman |
SELL
Open market or private sale
|
Indirect |
51,967
-0.86%
|
$3,221,954
$62.98 P/Share
|
|
Dec 12
2023
|
Atlas Venture Fund X, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
51,967
-0.86%
|
$3,221,954
$62.98 P/Share
|
|
Dec 12
2023
|
Atlas Venture Fund X, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
77,951
-0.71%
|
$4,832,962
$62.98 P/Share
|
|
Dec 12
2023
|
Orbimed Advisors LLC Director |
SELL
Open market or private sale
|
Indirect |
27,300
-1.2%
|
$1,638,000
$60.16 P/Share
|
|
Dec 12
2023
|
Mona Ashiya Director |
SELL
Open market or private sale
|
Indirect |
27,300
-1.2%
|
$1,638,000
$60.16 P/Share
|
|
Dec 12
2023
|
Joanne Bryce Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,500
-50.0%
|
$162,500
$65.22 P/Share
|
|
Dec 12
2023
|
Joanne Bryce Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+33.33%
|
$5,000
$2.65 P/Share
|
|
Dec 12
2023
|
William Richard White |
SELL
Open market or private sale
|
Direct |
33,511
-55.31%
|
$2,111,193
$63.63 P/Share
|
|
Dec 12
2023
|
William Richard White |
BUY
Exercise of conversion of derivative security
|
Direct |
33,511
+28.09%
|
$268,088
$8.67 P/Share
|